Creative Medical Technology Holdings (NASDAQ: CELZ) launched the BioDefense Inc. Veterans Initiative on Oct 30, 2025 to address long-term health effects from U.S. burn pit exposure using its proprietary iPSC regenerative platform and AI analytics.
The program will build a national-scale molecular database of toxic-exposure signatures, develop iPSC-based regenerative repair models, and deploy AI/ML exposure-classification and predictive-disease models. Greenstone Biosciences was named exclusive AI and iPSC development partner to provide sequencing, proteomics, and machine-learning support.
Creative Medical Technology Holdings (NASDAQ: CELZ) ha lanciato l’iniziativa Veterans di BioDefense Inc. il 30 ottobre 2025 per affrontare gli effetti sulla salute a lungo termine derivanti dall’esposizione agli burn pit americani utilizzando la sua piattaforma rigenerativa proprietaria iPSC e l’analisi basata sull’AI.
Il programma costruirà un database molecolare su scala nazionale di firme di esposizione tossica, svilupperà modelli rigenerativi basati su iPSC e impiegherà modelli di classificazione dell’esposizione e di malattia prevedibile basati su AI/ML. Greenstone Biosciences è stata nominata partner esclusivo di sviluppo AI e iPSC per fornire supporto di sequenziamento, proteomica e apprendimento automatico.
Creative Medical Technology Holdings (NASDAQ: CELZ) lanzó la Iniciativa para Veteranos de BioDefense Inc. el 30 de octubre de 2025 para abordar los efectos de salud a largo plazo por la exposición a las burn pits estadounidenses utilizando su plataforma regenerativa propietaria iPSC y análisis de IA.
El programa construirá una base de datos molecular a escala nacional de firmas de exposición tóxica, desarrollará modelos de reparación regenerativa basados en iPSC y desplegará clasificación de exposición y modelos de enfermedad predictivos basados en IA/ML. Greenstone Biosciences fue nombrado socio exclusivo de desarrollo de IA e iPSC para proporcionar secuenciación, proteómica y apoyo de aprendizaje automático.
Creative Medical Technology Holdings (NASDAQ: CELZ)는 2025년 10월 30일 BioDefense Inc. Veterans Initiative를 시작하여 미국의 burn pit 노출로 인한 장기 건강 영향에 대응하고 자사의 독점적인 iPSC 재생 플랫폼과 AI 분석을 활용합니다.
이 프로그램은 독성 노출 서명의 국가 규모의 분자 데이터베이스를 구축하고, iPSC 기반 재생 수리 모델을 개발하며, AI/ML 노출 분류 및 예측 질병 모델을 배포할 것입니다. Greenstone Biosciences가 AI 및 iPSC 개발의 독점 파트너로 선정되어 시퀀싱, 단백질체학 및 기계 학습 지원을 제공합니다.
Creative Medical Technology Holdings (NASDAQ: CELZ) a lancé l’Initiative Veterans de BioDefense Inc. le 30 octobre 2025 pour traiter les effets sur la santé à long terme liés à l’exposition des burn pits américains en utilisant sa plateforme régénératrice propriétaire iPSC et l’analyse IA.
Le programme construira une base de données moléculaire à l’échelle nationale des signatures d’exposition toxique, développera des modèles de réparation régénérative basés sur iPSC et déployera des modèles d’exposition et de maladie prédictive basés sur l’IA/ML. Greenstone Biosciences a été nommé partenaire exclusif de développement AI et iPSC pour fournir le séquençage, la protéomique et le soutien en apprentissage automatique.
Creative Medical Technology Holdings (NASDAQ: CELZ) startete die BioDefense Inc. Veterans Initiative am 30. Oktober 2025, um Langzeitauswirkungen von der Exposition gegenüber US-Burn-Pits mit seiner proprietären iPSC-Regenerationsplattform und KI-Analytik anzugehen.
Das Programm wird eine nationale molekulare Datenbank toxischer Expositionssignaturen aufbauen, iPSC-basierte regenerative Reparaturmodelle entwickeln und KI/ML-Expositionsklassifikation sowie prädiktive Krankheitsmodelle einsetzen. Greenstone Biosciences wurde zum exklusiven Partner für AI- und iPSC-Entwicklung ernannt, um Sequenzierung, Proteomik und maschinelles Lernen zu unterstützen.
Creative Medical Technology Holdings (NASDAQ: CELZ) أطلقت مبادرة BioDefense Inc. Veterans في 30 أكتوبر 2025 لمعالجة الآثار الصحية الطويلة الأمد الناجمة عن التعرض لبحيرات الحرق الأمريكية باستخدام منصتها التجديدية المالكة iPSC وتحليلات الذكاء الاصطناعي.
سيبني البرنامج قاعدة بيانات جزيئية على نطاق وطني لعلامات التعرض السامة، ويطور نماذج إصلاح تجديدية قائمة على iPSC، وينشر نماذج تصنيف التعرض والمرض التنبؤي المعتمدة على AI/ML. تم تعيين Greenstone Biosciences كشريك تطوير AI و iPSC حصري لتوفير التسلسل والتproteomics ودعم التعلم الآلي.
Positive
- Launched national BioDefense Inc. Veterans Initiative on Oct 30, 2025
- Named Greenstone Biosciences as exclusive AI and iPSC development partner
- Plans to create one of the largest molecular databases of veteran toxic exposure
- Combines proprietary iPSC platform with AI/ML for precision regenerative countermeasures
Insights
Creative Medical launches a national AI+iPSC program for veterans, partnering exclusively with Greenstone to build a large molecular exposure database.
Creative Medical creates BioDefense Inc. to collect molecular data and engineer iPSC‑based regenerative models, with Greenstone supplying AI, sequencing, and proteomics capabilities. The business mechanism links a proprietary cell platform to machine learning models to classify exposure and design targeted regenerative countermeasures.
Execution depends on successful large‑scale data collection, quality sequencing/proteomics, and integration of iPSC models with ML outputs. Regulatory review, data governance, participant recruitment, and technical validation pose material dependencies; each step must produce reproducible, clinically actionable outputs before therapeutic deployment.
Watch for concrete milestones: enrollment scale and database completion timelines, validation of exposure classification algorithms, and demonstration of iPSC model translational relevance within the next 12–36 months from
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform
PHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage leader in regenerative and cellular innovation, today announced the official launch of its BioDefense Inc. Veterans Initiative, believed to be a first-of-its-kind national program to combat the devastating long-term effects of toxic burn pit exposure among U.S. service members.
This initiative underscores the Company’s commitment to establishing a mission-critical role in America’s biodefense infrastructure by positioning Creative Medical as a cornerstone of national medical readiness and veteran health security. The program will utilize Creative Medical’s proprietary iPSC and regenerative repair technologies and algorithms, coupled with AI-powered analytics, to identify, model, and reverse toxic-exposure-related disease pathways.
Uniting Science, Service, and Sovereignty
BioDefense Inc., a subsidiary of Creative Medical, is spearheading the Burn Pit Exposure Molecular Characterization Program, designed to create one of the largest molecular-level databases of veteran toxic exposure in U.S. history. This platform will serve as the foundation for precision regenerative countermeasures, transforming the way respiratory, cardiovascular, and neurological damage from toxic exposure is diagnosed and treated.
“This is not just a scientific program, it’s a national imperative,” said Timothy Warbington, President and CEO of Creative Medical. “Our veterans gave everything for this country. Through BioDefense Inc., we’re giving them something back: cutting-edge regenerative technology born from American innovation, powered by AI, and built to secure the health of those who secured our freedom.”
Partnership with Greenstone Biosciences: Powering the AI Revolution in Regenerative Biodefense
To execute this disruptive initiative, Greenstone Biosciences, Inc., a Palo Alto–based biotechnology leader founded by Dr. Joseph C. Wu of Stanford University and recently partnered with NVIDIA 1,2, has been selected as the exclusive AI and iPSC development partner.
Under this partnership, Greenstone will deploy advanced molecular-sequencing, proteomic profiling, and machine-learning algorithms to analyze cellular data from service members exposed to burn pits. These AI-integrated systems will accelerate the creation of predictive exposure models and precision-engineered regenerative therapies—a groundbreaking leap in both biodefense and AI-enabled medicine.
“Greenstone’s machine learning and iPSC expertise will serve as the computational engine behind our national regenerative defense platform,” added Warbington. “Together, we’re not only redefining veteran healthcare, we’re building a scalable system that can respond to any biological threat, military or civilian.”
BioDefense Inc.: Establishing a New National Capability
BioDefense Inc. is executing a national program which will provide the critical data infrastructure to:
• Decode the genomic and proteomic architecture of toxic-exposure-related injury.
• Engineer iPSC-based regenerative repair models using Creative Medical’s patented cell platform.
• Validate next-generation AI/ML biodefense algorithms for exposure classification and precision intervention.
• Develop predictive, preemptive disease modeling systems for deployment across military and civilian populations.
Through this initiative, Creative Medical is establishing AI-integrated regenerative biodefense as a new national pillar of health security—uniting biotechnology, artificial intelligence, and patriotism into one transformative mission.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company driving innovation across regenerative medicine, immune modulation, and induced pluripotent stem cell (iPSC) technology. Its platform powers programs in autoimmune, inflammatory, neurological, metabolic, and biodefense medicine, integrating cellular regeneration and AI-enabled analytics to fortify national medical resilience. For more information, visit www.creativemedicaltechnology.com or www.biodefenseinc.com
About Greenstone Biosciences, Inc.
Greenstone Biosciences is a Palo Alto–based computational biotechnology company advancing AI-integrated drug discovery and iPSC modeling. Cofounded by Dr. Joseph C. Wu, Professor of Medicine and Radiology at Stanford University and Jade Chao, JD, MPH, Greenstone fuses automation, high-throughput biology, and computational modeling to accelerate the discovery of next-generation precision therapies. For more information, visit www.greenstonebio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements regarding expected results, potential benefits, and development timelines of the BioDefense Inc. burn pit exposure program and related collaborations. Actual results may differ materially due to various risks and uncertainties, including those detailed in Creative Medical Technology Holdings’ filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.
2 NVIDIA GTC Washington, DC: Live Updates on What’s Next in AI | NVIDIA Blog : NVIDIA Clara Open Models Jumpstart Scientific and Medical Collaboration at Scale
Contact:
Creative Medical Technology Holdings, Inc.
Investor Relations: IR@CreativeMedicalTechnology.com
Devin Sullivan, Managing Director – The Equity Group Inc.
dsullivan@theequitygroup.com
Conor Rodriguez, Associate – The Equity Group Inc.
crodriguez@theequitygroup.com
Dave Gentry – RedChip Companies
1-800-REDCHIP (733-2447)
CELZ@redchip.com
Greenstone Biosciences, Inc.
Investor Relations: jadechao@greenstonebio.com
Jade Chao, JD, General Counsel
jadechao@greenstonebio.com
(650) 714-7060
FAQ
What did Creative Medical (CELZ) announce on October 30, 2025 about veteran burn pit exposure?
Creative Medical announced the BioDefense Inc. Veterans Initiative to build a national molecular database and develop AI-enabled iPSC regenerative treatments for burn pit–related injuries.
Who is the exclusive AI and iPSC partner for Creative Medical’s BioDefense Initiative (CELZ)?
Greenstone Biosciences was selected as the exclusive AI and iPSC development partner to provide sequencing, proteomics, and machine-learning support.
How will Creative Medical (CELZ) use AI in the BioDefense Inc. program?
The company will use AI/ML to analyze molecular sequencing and proteomic data to build predictive exposure models and classify toxic-exposure–related disease pathways.
What capabilities will the BioDefense Inc. Veterans Initiative establish for CELZ?
The program aims to decode genomic/proteomic injury signatures, engineer iPSC regenerative repair models, and validate AI/ML biodefense algorithms for precision interventions.
Will the BioDefense Inc. program target specific organ systems for veterans exposed to burn pits?
Yes; the initiative targets respiratory, cardiovascular, and neurological damage associated with toxic burn pit exposure.
About the Author
